Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521535 | 0.94 | MEN1 (0.49) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL4565809 | 0.90 | MEN1 (0.40) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL30679137 | 0.86 | NPC1 (0.44) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL20973955 | 0.85 | NPC1 (0.40) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL27082137 | 0.85 | NPC1 (0.40) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL8752790 | 0.85 | NPC1 (0.41) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL31194380 | 0.84 | MDM2 (0.40) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL28191790 | 0.83 | NPC1 (0.39) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL28069714 | 0.82 | FABP5 (0.45) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL20586242 | 0.81 | KMT2A (0.48) | KMT2AMEN1NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12098218-B2 | Process for the manufacture of degarelix and its intermediates | Fresenius Kabi iPSUM S.r.l (IT) | 2024-09-24 | — | — | US | disclosed |
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-06-09 | — | — | US | disclosed |
| US-11332495-B2 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | RK Pharma Solutions LLC (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3981781-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-04-13 | — | — | EP | disclosed |
| CN-108779150-B | Preparation method of degarelix and intermediate thereof | 费森尤斯卡比依普莎姆责任有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220033443-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l (IT) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | VIP, PEPD, SSTR4 | KMT2A 1346/4885MEN1 2432/4885NPC1 4260/4885 |
| US-11332495-B2 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | PEPD, DNPEP, PREP | KMT2A 2862/4885MEN1 138/4885NPC1 3441/4885 |
| US-20220033443-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | ANPEP, DNPEP, NPPA | KMT2A 1638/4885MEN1 2301/4885NPC1 3482/4885 |
| US-12098218-B2 | Process for the manufacture of degarelix and its intermediates | ANPEP, DNPEP, NPPA | KMT2A 1638/4885MEN1 2301/4885NPC1 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.